New Zealand markets open in 3 hours 45 minutes

PFE Mar 2025 37.500 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.4100-0.0200 (-4.65%)
As of 11:05AM EST. Market open.
Full screen
Previous close0.4300
Open0.4000
Bid0.3700
Ask0.4100
Strike37.50
Expiry date2025-03-21
Day's range0.3900 - 0.4200
Contract rangeN/A
Volume16
Open interest810
  • Investor's Business Daily

    Is Pfizer Stock A Sell After Two Years In Free Fall? Or Will Seagen Bolster Sales?

    Pfizer stock remains under pressure despite becoming one of the biggest names of the pandemic. Is PFE stock a sell?

  • Insider Monkey

    OPKO Health, Inc. (NASDAQ:OPK) Q4 2023 Earnings Call Transcript

    OPKO Health, Inc. (NASDAQ:OPK) Q4 2023 Earnings Call Transcript February 27, 2024 OPKO Health, Inc. reports earnings inline with expectations. Reported EPS is $-0.09 EPS, expectations were $-0.09. OPKO Health, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good […]

  • Reuters

    Pfizer says its RSV shot is protective through a second year

    Pfizer on Thursday said a single dose of its new respiratory syncytial virus (RSV) vaccine Abrysvo maintained its ability to protect against the illness through a second year of respiratory disease season. The company said in a press release that the vaccine's efficacy against RSV-associated lower respiratory tract disease with three or more symptoms was 77.8% through season two, compared with efficacy of 88.9% after the first RSV season, which led to the shot's U.S. approval. Cumulative efficacy over both seasons after around 16.4 months of disease surveillance was 81.5%, Pfizer said.